Physician profile
Clement Adedejo Ogunwande
NPI 1295828127
$612.89
in general payments reported to CMS, 2019-2025
13 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.21 · 2020: $16.50 · 2022: $117 · 2024: $81.35 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kvk-Tech, INC. | $196.90 | 2025 | |
| Lilly USA, LLC | $78.71 | 2019-2025 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $67.55 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.80 | 2022 | |
| Merck Sharp & Dohme LLC | $40.56 | 2024-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Tactile Systems Technology INC | $36.73 | 2025 | Nimbl, Flexitouch Plus |
| Exact Sciences Corporation | $30.54 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $29.00 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $20.86 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $17.22 | 2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $15.70 | 2024 | Breztri |
| Astellas Pharma US INC | $15.65 | 2025 | Veozah |
| Amgen INC. | $13.67 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clement Ogunwande listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.